• Save
Global Intravenous (IV) Iron Drugs Market Report: 2013 Edition- Koncept Analytics
Upcoming SlideShare
Loading in...5
×
 

Like this? Share it with your network

Share

Global Intravenous (IV) Iron Drugs Market Report: 2013 Edition- Koncept Analytics

on

  • 1,301 views

With the dawn of novel technology era, companies operating in the healthcare/science/pharmaceutical/therapeutic industries are now surmounting the never touched peaks. Also the growth of these ...

With the dawn of novel technology era, companies operating in the healthcare/science/pharmaceutical/therapeutic industries are now surmounting the never touched peaks. Also the growth of these industries is overhauled by the unrelenting increase in health related issues emanating from the altering lifestyle and rapidly evolving surrounding environment. Amongst the respective industries of biological sciences, a booming industry is of IV (Intravenous) iron.

Iron is one of the most crucial elements required by the human body. It is a component of hemoglobin, the substance present in RBCs that transports oxygen throughout the body via blood. This oxygen is used by the cells for generating energy required to perform the necessary body functions. So, if the body’s iron levels fall below the accepted line, it can lead to severe health problems. Usually oral iron supplements are recommended for restoring and maintaining iron levels in the body, but oral treatment has certain limitations. For the cases where oral supplements are incapable of fulfilling the purpose, IV iron therapy is used as part of which iron is directly injected with a needle into a vein.

This report offers comprehensive analysis of the global iron products market along with the key segments viz. IV Iron and Oral Iron. Herein, the IV iron market is discussed in details. Also, the IV iron replacement therapy market of the US is covered. Furthermore, market dynamics including the key trends and developments, underlying industry growth drivers and the challenges faced by the respective market are analyzed in-depth. On the contention front, the market for IV iron is highly competitive with a handful of players dominating the whole market. The competitive landscape along with the profiles of leading industry players is also included in this report.

Statistics

Views

Total Views
1,301
Views on SlideShare
1,301
Embed Views
0

Actions

Likes
1
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Global Intravenous (IV) Iron Drugs Market Report: 2013 Edition- Koncept Analytics Presentation Transcript

  • 1. Global Intravenous (IV) Iron Drugs Market------------------------------------------------------------2013View Report Details
  • 2. Executive SummaryWith the dawn of novel technology era, companies operating in the healthcare/science/pharmaceutical/therapeutic industries arenow surmounting the never touched peaks. Also the growth of these industries is overhauled by the unrelenting increase in healthrelated issues emanating from the altering lifestyle and rapidly evolving surrounding environment. Amongst the respectiveindustries of biological sciences, a booming industry is of IV (Intravenous) iron.Iron is one of the most crucial elements required by the human body. It is a component of hemoglobin, the substance present inRBCs that transports oxygen throughout the body via blood. This oxygen is used by the cells for generating energy required toperform the necessary body functions. So, if the body’s iron levels fall below the accepted line, it can lead to severe healthproblems. Usually oral iron supplements are recommended for restoring and maintaining iron levels in the body, but oraltreatment has certain limitations. For the cases where oral supplements are incapable of fulfilling the purpose, IV iron therapy isused as part of which iron is directly injected with a needle into a vein.This report offers comprehensive analysis of the global iron products market along with the key segments viz. IV Iron and OralIron. Herein, the IV iron market is discussed in details. Also, the IV iron replacement therapy market of the US is covered.Furthermore, market dynamics including the key trends and developments, underlying industry growth drivers and the challengesfaced by the respective market are analyzed in-depth. On the contention front, the market for IV iron is highly competitive with ahandful of players dominating the whole market. The competitive landscape along with the profiles of leading industry players isalso included in this report.By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the futuregrowth of the industry. We employed various significant variables that have an impact on this industry and created regressionmodels with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationshipbetween several independent or predictor variables and the dependent variable was analyzed using standard SPSS output,including charts, tables and tests.View Report Details
  • 3. The balance of iron in the body primarily is a combined result of three dynamics- intake, losses andmetabolic demand…•Iron is among the most crucial elements required for red blood cellproduction, and iron homeostasis i.e. the body’s internal regulation ofiron. It is one of the key functions which gets disrupted in dialysispatients. Iron deficiency, either absolute or functional, is a primarycause of anemia in hemodialysis patients.•The worldwide market for iron related products was valued atUS$.......... billion in 2012, experiencing a decline of ………% againstUS$............. billion in 2011. Over the time span of 4 years from 2008 to2012, the global market for iron products recorded a CAGR of ……….%and increased from US$..........billion in 2008 to US$................billion in2012.•As of 2012, the overall iron products market was dominated by the oraliron medication with share worth …………% while IV iron constitutedthe remaining …………….% of the respective market.Industry Trends and Developments-New Product Development- Soluble Ferric Pyrophosphate (SFP)-Bundled Payment SystemChallenges-Stringent Regulation-Concerns Regarding Adverse EffectsOral IntavenousGlobal Iron Products Market (2008-2012)Global Iron Products Market Share (2012)2008 2009 2010 2011 2012US$Billion
  • 4. The cases, where oral supplements fail to meet the requirement, IV iron therapy is used, as part of whichiron is directly injected with a needle into a vein….•The IV iron market was valued at US$...........million in 2011, andregistered a decline of …….% to US$...... million in 2012. During 2008-2012, the worldwide market for IV iron increased at the compoundannual growth rate of …….%.•In the US, at present there are three primary IV iron agents viz.Venofer (iron sucrose), Ferrlecit (sodium ferric gluconate), andFeraheme (ferumoxytol) which are used in dialysis facilities for treatingiron deficiency. As of 2011, the US IV iron market reachedUS$...........million recording a decline of ……..% as compared to thevalue of US$.........million in 2010.•On an estimated basis, the size of the total 2012 US non-dialysis IViron replacement therapy market was approximately …………. grams,which depicted an increase of nearly ……..% over 2011 when the sizewas ………. grams.US Non-Dialysis IV Iron Market (2011 & 2012)The US IV Iron Market Size (2008-2011))Global IV Iron Market (2008-2012)2008 2009 2010 2011US$Million2008 2009 2010 2011 2012US$Million20112012Grams
  • 5. Branded IV iron products include Venofer, Ferrlecit, Monofer, Ferinject (ferric carboxymaltose injection)and certain other iron dextran and iron sucrose products….As per the estimates, the total size of the US non-dialysis IV iron replacement therapy market observed an increaseof approximately ………% over 2011. The leading product in the year 2012, in the US non-dialysis IV iron market wasVenofer with ……..% market share.Oral iron is currently the first-line iron replacement alternative preferred by majority of the physicians in both the USand abroad. IV irons are best suited for those patients whose ferritin, fundamentally storage iron, levels have beenprofoundly depleted.There are five key IV irons that are on the market or in development: Watson’s INFeD, Luitpold Pharmaceuticals’Venofer, Sanofi’s Ferrlecit, AMAG Pharmaceuticals’ Feraheme, and Luitpold’s Injectafer.The global IV iron market, which is estimated to reach US$........ million in 2015 from US$.........million in 2012. Duringthe 3 year period from 2012 to 2015, the global market for IV iron is expected to grow at a CAGR of ……….%.Note: Market attractiveness is inverse of penetration. Low penetration means high attractiveness and vice-versa2010 2011 2012 2013E 2014E 2015EUS$BillionGlobal IV Iron Market Forecast (2010-2015E)Venofer Luitpold Pharm Inc. BrandVenofer Fresenius Kabi Branded GenericNulecit Watson Pharma Branded GenericInfed Watson Pharma Branded GenericFerrlecit Sanofi Aventis Branded GenericFeraheme AMAG Pharm Branded GenericOthersIV Iron Market Share in the US (January 2012)
  • 6. Table of Contents1. Iron in Human Body: An Overview1.1 IV Iron Application Areas1.1.1 IV Iron Application in Nephrology1.2 Iron Deficiency- Anemia1.3 IV Iron Therapy for Anemia Treatment2. Iron Medication Market Structure2.1 Global Iron Products Market-Market Value-Market Segments2.1.1 Global IV Iron Market-Market Value2.2 The US IV Iron Market-Market Value-Non-Dialysis IV Iron Market3. Market Dynamics3.1 Industry Trends and Developments3.1.1 New Product Development- Soluble FerricPyrophosphate (SFP)3.1.2 Bundled Payment System3.2 Growth Drivers3.2.1 Increasing Use of IV Iron in Gynecology3.2.2 IV Iron Improves Quality of Treatment outsideDialysis3.2.3 Increasing Dialysis Patient Population3.2.4 Growing Number of Diabetic Patients Worldwide3.2.5 Increasing Cases of HypertensionList of Charts & TablesList of ChartsGlobal Iron Products Market (2008-2012)Global Iron Products Market Share (2012)Global IV Iron Market (2006-2010)The US IV Iron Market Size (2008-2011)US Non-Dialysis IV Iron Market (2011 & 2012)IV Iron – Avoidance of ESA Initiation in Pre Dialysis PatientsIV Iron – Response Rate to ESA with/without IV Iron (2004-2011)Dialysis Patient Population Worldwide (2005-2015E)Dialysis Patient Population Share by Region (2011)Global Diabetes Population (2006-2011)Causes of ESRD in the US (2011)Worldwide Patients with End Stage Renal Disease (2005-2011)Hypertension Prevalence in the US (2010-2015E)Hypertension Prevalence in the Developed Europe (2010-2015E)Global Healthcare Spending (2005-2015E)Global Spending on Medicines (2006-2016E)Global Spending on Medicine Share by Region (2006-2016E)The US Spending on Medicine (2007-2016E)Japan’s Spending on Medicine (2007-2016E)Global Ageing Population (2005-2013F)Global GDP (2001-2011)World GDP per Capita (2005-2011)Global Insurance Density (2004-2011)Long and Short Term Concerns about IV IronIV Iron Market Share in the US (January 2012)Galenica’s Revenue Share by Business Segments (2012)Galenica’s Net Sales and Net profit (2009-2012)Actavis’ Revenue Share by Business Segment (2012)Actavis’ Revenues and Net Income (2009-2012)AMAG Pharmaceuticals’ Revenues (2009-2012)Global IV Iron Market Forecast (2010-2015E)
  • 7. 3.2.6 Rising Healthcare Expenditure3.2.7 Higher Spending on Medicines3.2.8 Growing Ageing Population (+60 Years)3.2.9 Ameliorating Economic Conditions3.2.10 Increasing Insurance Density3.3 Challenges3.3.1 Stringent Regulation3.3.2 Concerns Regarding Adverse Effects4. Competitive Landscape4.1 US Market4.2 Product Contention5. Company Profiles5.1 Galenica Pharmaceuticals5.1.1 Business Overview5.1.2 Financial Overview5.1.3 Business Strategies-Strong Foothold in Healthcare Market-Focus on New Product Development5.2 Actavis Inc.5.2.1 Business Description5.2.2 Financial Overview5.2.3 Business Strategies-Strategic Acquisitions-Intense R&D Activities5.3 AMAG Pharmaceuticals5.3.1 Business Oveview5.3.2 Financial Overview5.3.3 Business Strategies-Focus on Research & Development-Expanding the Existing LabelsList of TablesRisk Factors for CKDSFP Clinical TrialsIV Iron Products – Safety ProfileThe US Non-Dialysis IV Iron Market (2011 & 2012)IV Iron Administration ComparisonDependent & Independent Variables (2006-2010)Correlation MatrixModel Summary – Coefficient of DeterminationRegression Coefficients Output
  • 8. 6. Market Outlook6.1 Market Forecast6.2 Forecast Methodology6.2.1 Dependent and Independent Variables6.2.2 Correlation Analysis6.2.3 Regression Analysis
  • 9. Koncept AnalyticsCS-36, Second Floor, Ansal PlazaVaishali, Ghaziabad,U.P. – 201010T. +91-120-4130959C: +91-9811715635vikas@konceptanalytics.comContact Us:www.konceptanalytics.comVikas GuptaBD ManagerThese are abridged and sanitized sample pages from the comprehensive report on the “Global Intravenous (IV) Iron DrugsMarket ”. To know more about this report or for any customized research requirement, please contact the following:View Report Details